A pair of late-stage trials conducted by Eli Lilly found that their experimental once-weekly insulin can effectively lower blood sugar levels, comparable to daily insulins currently in use. This announcement by the drugmaker on Thursday has intensified the competition with Novo Nordisk in the development of longer-acting insulins, showcasing the ongoing race for innovation in diabetes treatment. The results highlight the potential of Eli Lilly’s new insulin therapy to offer a convenient and effective option for managing diabetes.
Source link
Loading PerspectiveSplit analysis...
